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Background
The nationwide statistical analysis of hematologic malignancies in Korea has not been 
reported yet. 
Methods 
The Korea Central Cancer Registry and the Korean Society of Hematology jointly inves-
tigated domestic incidence rates and prevalence of hematologic malignancies occurred 
between 1999 and 2008, and analyzed survival rates of patients who were diagnosed be-
tween 1993 and 2008. Data of hematologic malignancies from 1993 to 2008 were ob-
tained from the Korean National Cancer Incidence Data base. The crude incidence rates, 
age-specific incidence rates, age-standardized incidence rates, annual percentage change 
of incidence, and prevalence from 1999-2008 were calculated. Survival rates for patients 
diagnosed in 1993-2008 were estimated.
Results
In 2008, a total of 8,006 cases of hematologic malignancies were occurred, which com-
prised 4.5% of all malignancies. In all genders, non-Hodgkin lymphoma, myeloid leuke-
mia, and multiple myeloma were most frequent diseases. In terms of age, ages between 
60 and 69 were most prevalent. From 1999 to 2008, the age-standardized incidence rates 
increased from 10.2 to 13.7, and the annual percentage change was 3.9%. The 5-year 
survival rate increased from 38.2% during 1993-1995 to 55.2% during 2004-2008. As 
of January 2009, number of patients with 10-year prevalence was 33,130, and with 5- 
to 10-year prevalence was 10,515. 
Conclusion
This is the first nationwide statistical report of hematologic malignancies in Korea. It could 
be used as the basic information to help investigate epidemiologic characteristics, eval-
uate progress during the past years, and establish future strategies for hematologic 
malignancies. Periodic statistical analysis of hematologic malignancies in Korea should 
be continued.
Key Words Hematologic malignancy, Incidence, Survival, Prevalence, Korea
*This work was supported by a research 
grant from the National Cancer Center 
(No. 1010160).
Correspondence to
Sohee Park, Ph.D.
The Korea Central Cancer Registry, 
Division of Cancer Registration and 
Surveillance, National Cancer Center, 323 
Ilsan-ro, Ilsandong-gu, Goyang 410-769, 
Korea
Tel: ＋82-31-920-2015 
Fax: ＋82-31-920-2179
E-mail: shpark@ncc.re.kr
Ⓒ2012 Korean Society of Hematology
INTRODUCTION
The field of hematologic malignancies has continuously 
advanced for past 50 years in Korea. However, much less 
attention was paid for its cancer statistical analysis. There 
has not been a report that analyzed the incidence rate, preva-
lence rate, and survival rate of the whole nationwide hemato-
logic malignancies and this is also comparable to other devel-
oped countries [1, 2]. There are several reasons for the diffi-
culty of analysis. The classification of hematologic malig-
nancies is constantly changing, and cancer registry in each 
country has different definitions for the subtypes of hemato-
logic malignancies, which jeopardizes the quality of patient 
data and all these reasons make it difficult to compare hema-
tologic statistics according to time and region. Since 2005, 
USA and Europe integrated recent International Classification 
of Diseases-Oncology (ICD-O) and World Health Organiza-Korean J Hematol 2012;47:28-38.
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Table 1. Classification of hematologic malignancies according to 
ICD-10.
Cancer type ICD-10 code (ICD-O-3 code)
Hodgkin lymphoma C81
Non-Hodgkin lymphoma C82-C85, C96
Multiple myeloma C90
Lymphoid leukemia C91
Myeloid leukemia C92-C94
MPD (M9950/3, 996_/3, 9975/3)
MDS (M998_/3)
Abbreviations: MPD, myeloproliferative disorders; MDS, myelo-
dysplastic syndromes.
tion (WHO) classification and with agreements of experts, 
they classified statistics on hematologic malignancies that 
fit the objectives of epidemiology and public health care, 
and published the statistical reports [3-5].
In an effort to determine the characteristics of domestic 
hematologic malignancies and analyze past survival rates 
to establish the barometer for creating strategies for the 
advancement of domestic hematologic malignancies field, 
the Korea Central Cancer Registry and the Korean Society 
of Hematology jointly investigated the domestic prevalence 
rate and incidence rate of hematologic malignancies occurred 
between 1999 and 2008, and analyzed survival rate of patients 
who were diagnosed as hematologic malignancies between 
1993 and 2008.
MATERIALS AND METHODS
Data of hematologic malignancies from 1993 to 2008 were 
obtained from the Korean National Cancer Incidence Data 
base (KNCIDB) [6]. Hematologic malignancies were classified 
according to the International Classification of Diseases for 
Oncology 3rd edition (ICD-O-3) and converted to the 
International Classification of Diseases 10th edition (ICD-10) 
(Table 1) [7, 8]. For myeloproliferative disorders (MPD) and 
myelodysplastic syndromes (MDS), official registration em-
ploying ICD-O-3 began in 2003 at Korea Central Cancer 
Registry (KCCR).
Crude incidence rates (CRs) and age-specific incidence 
rates of each hematologic malignancy were calculated. The 
CRs per 100,000, an incidence rate based on the frequency 
of cancer in the entire population, were calculated by divid-
ing the total number of events (N) by the total number 
of person-year of observation (P) and multiplying the result 
by 100,000. The age-specific incidence rates per 100,000 
within age group i, were calculated by dividing the number 
of incidence observed in the age group (N i) by the number 
of corresponding person-year of observation (Pi) and multi-
plying the result by 100,000. Age-standardized incidence 
rates (ASRs), a weighted average of crude age-specific rates, 
were determined by using the mid-year population in Korea 
in 2000 as standard population. Changes in the annual ASRs 
were examined by calculating the annual percentage change 
(APC) over a time period as (exp(b)-1)×100, where b is the 
slope of the regression of log(ASR) on a calendar year as 
the following linear regression equation [9]:
E(log(ASR)|year)=a+b year.
The survival analysis used cases of hematologic malig-
nancies first diagnosed during 1993-2008 from KNCIDB, 
and the vital status of these patients were followed through 
December 31, 2010. The survival duration of each case was 
determined as the time difference between the date of initial 
diagnosis and the date of death, date of loss to follow up, 
or closing date for follow-up. Observed survival rates were 
calculated using a life table method, in which survival times 
are grouped into intervals [10]. Limited-duration prevalent 
cases are the number of cancer patients alive on a certain 
day who had been diagnosed with the disease within the 
past specified years. For example, 10-year prevalent cases 
in this report were the patients that were diagnosed between 
1999 and 2008 and were alive on January 1, 2009. The lim-
ited-duration prevalence, such as 1, 5, and 10-year prevalence 
was calculated using SEER*Stat software [11].
RESULTS
1. Incidence
A total national cancer incident cases in 2008 were 178,816 
cases. Stomach cancer (15.7%) was most prevalent, followed 
by thyroid cancer (15.1%), colorectal cancer (12.7%), lung 
cancer (10.5%), liver cancer (8.8%), and breast cancer (7.1%). 
Hematologic malignancies occurred in 8,006 patients, which 
was 4.5% of all cancers next to breast cancer. It occurred 
in 4,486 men and 3,520 women, and this relates to 4.8% 
of all cancers occurred in men, and 4.1% of all cancers 
occurred in women (Fig. 1). Among all hematologic malig-
nancies, non-Hodgkin lymphoma (NHL) was most frequent, 
followed by myeloid leukemia, and multiple myeloma re-
gardless of gender. Ages between 60 and 69 were most preva-
l e n t  f o l l o w e d  b y  a g e s  7 0  t o  7 9 ,  a n d  a g e s  5 0  t o  5 9  ( Fig. 
2). Lymphoid leukemia was most prevalent in ages below 
15 years in both genders while NHL was most prevalent 
in ages above 15 years (Table 2).
The trends in number of patients, CRs, and ASRs for 
each hematologic malignancy between 1999 and 2008 are 
described in Table 3. The overall ASRs of hematologic malig-
nancies increased from 10.2 in 1999 to 13.7 in 2008. The 
APC was 3.9% between 1999 and 2008 which was higher 
than 3.3% in all cancers, and APCs were statistically sig-
nificant in all hematologic malignancies. For age-specific 
incidence rates in 2008, lymphoid leukemia was the highest 
in age under 15 years regardless of gender. In both genders, 
age-specific incidence rates of all hematologic malignancies, 
except for lymphoid leukemia, increased as age increased; 
however, age-specific incidence rate decreased after age of 
80 in women (Fig. 3). Korean J Hematol 2012;47:28-38.
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Fig. 1. Relative frequency of hema-
tologic malignancies in Korea, 
2008. (A) Men. (B) Women.
Fig. 2. Incident cases of hematologic malignancies by age group in 
Korea, 2008.
2. Survival rates
The survival of all hematologic malignancies continually 
increased from 1993 to 2008 with 5-year survival rate of 
38.2% between 1993 and 1995 to 55.2% between 2004 and 
2008, an increase of 17% (Fig. 4). The survival rates increased 
from 68.5% to 80.9% in Hodgkin lymphoma (HL), from 
47.6% to 62.8% in NHL, from 22.9% to 33.2% in multiple 
myeloma, from 38.9% to 52.4% in lymphoid leukemia, and 
from 21.9% to 44% in myeloid leukemia. Survival rate of 
women were slightly higher or similar to men, but in MDS, 
men had 36.4% of survival rate while women had 50.3%, 
showing differences.
Survival rate decreased as age increased in most of the 
hematologic malignancies, and when the age of diagnosis 
was above 50 years old, the survival rate was even more 
decreased (Table 4). However, there is a marked difference 
of survival rate in lymphoid leukemia between groups of 
diagnostic age of 0-14 years and above 15 years. Five year 
survival rates according to hematologic malignancies, year, 
gender and age are described in Table 4.
3. Prevalence
As of January 2009, the total number of patients with 
10 year-prevalence who were diagnosed as hematologic ma-
lignancies was 33,130, which comprised 4.6% of total 10 
year-prevalence in all cancers. In terms of prevalent cases, 
the number of patients less than 1 year was 6,548, 1-2 years 
5,024, 2-5 years 11,043, and 5-10 years 10,515 (Fig. 5). 
Patients with more than 5 year-prevalence comprised 32%. 
NHL was most frequent with 16,142 patients, followed by 
myeloid leukemia and lymphoid leukemia with 6,068 and 
3,066 patients, respectively.
DISCUSSION
This is the first study to analyze hematologic malignancies, 
providing a statistical information on all hematologic malig-
nancies in Korea. As with all other cancers, the incidence 
of hematologic malignancies has been increasing. In compar-
ison with other countries, almost no differences can be seen 
with Japan and China in the incidences of hematologic malig-
nancies, however, in comparison with western countries 
including United Kingdom, France, Germany, and Canada, 
our incidences of HL, NHL, and multiple myeloma were 
lower, showing distinct differences (Table 5) [12]. This could 
be regarded as the reflection of differences in race; however, 
we observed the recent increase of HL, NHL, and multiple 
myeloma in our country.
MDS and MPD have been officially registered in Korea 
cancer registry since 2003. USA also began their registration 
of MDS and MPD in central registry in 2001. According 
to the analysis of MDS registered in the Surveillance, 
Epidemiology, and End Results (SEER) and North American 
Association of Cancer Registry between 2001 and 2004, the Korean J Hematol 2012;47:28-38.
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Table 2. Ranks of age-specific incidence rates of hematologic malignancies by gender and age group in Korea, 2008.
Rank
Age (yr)
0-14 15-34 35-49 50-64 65-79 ≥80
Men
    1      LL (2.8)  NHL (2.4) NHL (6.3)  NHL (14.8)  NHL (32.4)  NHL (46.3)
    2  NHL (1.4)    ML (2.1) ML (3.1)    ML (6.1)    ML (12.6)    ML (15.0)
    3    ML (1.4)      LL (0.8) MPD (1.0)   MM (4.8)   MM (11.6)   MM (14.5)
    4     HL (0.2)     HL (0.6) MM (0.7) MDS (2.6) MDS (8.9) MDS (10.1)
    5 MDS (0.1) MPD (0.4) MDS (0.7) MPD (2.4) MPD (5.7) MPD (5.7)
    6 MPD (0.02) MDS (0.3) LL (0.7)      LL (1.5)      LL (2.6)      LL (2.2)
    7   MM (0)   MM (0.1) HL (0.3)     HL (0.6)     HL (1.4)     HL (1.8)
Women
    1      LL (2.5)  NHL (2.3) NHL (4.7)   NHL(10.8)  NHL (20.4)  NHL (19.4)
    2    ML (1.0)    ML (1.8) ML (2.7)    ML (4.1)   MM (8.2)    ML (5.7)
    3  NHL (0.9)     HL (0.5) MDS (0.8)   MM (3.9)    ML (7.9)   MM (3.8)
    4 MDS (0.1)      LL (0.5) MPD (0.7) MPD (1.9) MDS (3.9) MDS (3.2)
    5     HL (0.1) MDS (0.3) LL (0.6) MDS (1.5) MPD (3.7) MPD (2.3)
    6 MPD (0.1) MPD (0.3) MM (0.6)      LL (1.1)      LL (1.3)      LL (0.5)
    7   MM (0)   MM (0.03) HL (0.1)     HL (0.4)     HL (0.7)     HL (0.4)
Incidence rates per 100,000 are in parenthesis.
Abbreviations: LL, lymphoid leukemia; NHL, non-Hodgkin lymphoma; ML, myeloid leukemia; HL, Hodgkin lymphoma; MM, multiple 
myeloma; MPD, myeloproliferative disorders; MDS, myelodysplastic syndromes.
Table 3. Number of hematologic malignancies and trend in crude incidence rates and age-standardized incidence rates in Korea from 1999 to 
2008.
Cancer type Gender
Year
APC
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Hematologic Total   Cases 4,735 4,620 5,215 5,466 6,087 6,484 6,837 7,131 7,623 8,006 
  malignancies   CR 10.0  9.7 10.9 11.4 12.6 13.4 14.0 14.6 15.5 16.2 
  (Total)   ASR 10.2  9.7 10.7 11.0 12.0 12.4 12.7 13.0 13.4 13.7    3.9
b)
Men   Cases 2,747 2,640 2,987 3,201 3,439 3,719 3,831 3,994 4,325 4,486 
  CR 11.6 11.1 12.4 13.3 14.2 15.3 15.7 16.3 17.6 18.1 
  ASR 12.7 11.9 13.2 13.8 14.5 15.3 15.3 15.5 16.3 16.3    3.4
b)
Women   Cases 1,988 1,980 2,228 2,265 2,648 2,765 3,006 3,137 3,298 3,520 
  CR 8.5  8.4  9.3  9.4 11.0 11.4 12.4 12.9 13.5 14.3 
  ASR 8.1 7.9 8.7 8.8 9.9  10.1  10.6  10.9  11.0  11.6    4.5
b)
Hodgkin Total  Cases 121 135 148 144 158 204 157 172 200 210
 lymphoma  CR 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.4 0.4 0.4
 ASR 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.4 0.4  4.5
b)
Men  Cases 85 89 100 83 112 145 105 106 127 127
 CR 0.4 0.4 0.4 0.3 0.5 0.6 0.4 0.4 0.5 0.5
 ASR 0.4 0.4 0.4 0.4 0.5 0.6 0.4 0.4 0.5 0.5  2.8
W o m e n  C a s e s 3 64 64 86 14 65 95 26 67 38 3
 CR 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.3 0.3 0.3
 ASR 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.3 0.3 0.3  7.2
b)
Non-Hodgkin Total  Cases 2,176 2,093 2,303 2,400 2,666 2,892 3,013 3,210 3,353 3,475
 lymphoma  CR 4.6 4.4 4.8 5.0 5.5 6.0 6.2 6.6 6.8 7.0
 ASR 4.7 4.4 4.7 4.8 5.2 5.5 5.6 5.8 5.8 5.8  3.3
b)
Men  Cases 1,281 1,246 1,356 1,397 1,522 1,667 1,680 1,830 1,931 1,936
 CR 5.4 5.2 5.6 5.8 6.3 6.9 6.9 7.5 7.8 7.8
 ASR 6.1 5.7 6.1 6.1 6.4 6.8 6.7 7.0 7.2 7.0  2.4
b)
Women  Cases 895 847 947 1,003 1,144 1,225 1,333 1,380 1,422 1,539
 CR 3.8 3.6 4.0 4.2 4.8 5.1 5.5 5.7 5.8 6.2
 ASR 3.6 3.3 3.6 3.8 4.2 4.4 4.6 4.7 4.6 4.9  4.4
b)
Multiple Total  Cases 466 487 561 563 615 671 785 765 882 893
 myeloma  CR 1.0 1.0 1.2 1.2 1.3 1.4 1.6 1.6 1.8 1.8
 ASR 1.0 1.0 1.1 1.1 1.2 1.2 1.4 1.3 1.4 1.4  3.8
b)
Men  Cases 254 271 314 326 331 359 403 382 455 480
 CR 1.1 1.1 1.3 1.3 1.4 1.5 1.7 1.6 1.8 1.9
 ASR 1.3 1.3 1.5 1.4 1.4 1.5 1.6 1.4 1.6 1.6  2.7
b)Korean J Hematol 2012;47:28-38.
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Table 3. Continued.
Cancer type Gender
Year
APC
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Women  Cases 212 216 247 237 284 312 382 383 427 413
 CR 0.9 0.9 1.0 1.0 1.2 1.3 1.6 1.6 1.7 1.7
 ASR 0.8 0.8 0.9 0.8 1.0 1.0 1.2 1.1 1.2 1.2  5.1
b)
Lymphoid Total  Cases 549 497 541 557 550 534 554 595 598 601
 leukemia  CR 1.2 1.0 1.1 1.2 1.1 1.1 1.1 1.2 1.2 1.2
 ASR 1.2 1.0 1.1 1.2 1.1 1.1 1.1 1.2 1.2 1.2  1.2
b)
Men  Cases 314 281 315 336 302 304 328 327 339 346
   CR 1.3 1.2 1.3 1.4 1.2 1.3 1.3 1.3 1.4 1.4
 ASR 1.3 1.2 1.3 1.4 1.3 1.3 1.4 1.4 1.4 1.4    1.1
Women  Cases 235 216 226 221 248 230 226 268 259 255
 CR 1.0 0.9 0.9 0.9 1.0 1.0 0.9 1.1 1.1 1.0
 ASR 1.0 0.9 1.0 0.9 1.0 1.0 0.9 1.1 1.1 1.1 1.5
b)
Myeloid Total  Cases 1,216 1,156 1,325 1,380 1,394 1,495 1,450 1,500 1,535 1,661
 leukemia  CR 2.6 2.4 2.8 2.9 2.9 3.1 3.0 3.1 3.1 3.4
 ASR 2.6 2.4 2.7 2.8 2.8 2.9 2.8 2.8 2.8 3.0 1.4
b)
Men  Cases 691 619 718 796 757 846 804 832 869 931
 CR 2.9 2.6 3.0 3.3 3.1 3.5 3.3 3.4 3.5 3.8
 ASR 3.1 2.7 3.1 3.4 3.2 3.5 3.2 3.3 3.3 3.5    1.6
b)
Women  Cases 525 537 607 584 637 649 646 668 666 730
 CR 2.2 2.3 2.5 2.4 2.6 2.7 2.7 2.7 2.7 3.0
 ASR 2.2 2.2 2.4 2.3 2.4 2.5 2.4 2.4 2.4 2.5 1.3
b)
MPD
a) Total  Cases 307 290 414 420 523 552
 CR 0.6 0.6 0.9 0.9 1.1 1.1
 ASR 0.6 0.5 0.8 0.7 0.9 0.9 10.9
b)
Men  Cases 182 152 231 225 302 305
 CR 0.8 0.6 0.9 0.9 1.2 1.2
 ASR 0.8 0.6 0.9 0.9 1.1 1.1 10.3
b)
Women  Cases 125 138 183 195 221 247
 CR 0.5 0.6 0.8 0.8 0.9 1.0
 ASR 0.4 0.5 0.6 0.6 0.7 0.8 11.7
b)
MDS
a) Total  Cases 397 398 464 469 532 614
 CR 0.8 0.8 1.0 1.0 1.1 1.2
 ASR 0.8 0.7 0.8 0.8 0.9 1.0 5.2
b)
Men  Cases 233 246 280 292 302 361
 CR 1.0 1.0 1.1 1.2 1.2 1.5
 ASR 1.0 1.0 1.1 1.1 1.1 1.3 4.1
b)
Women  Cases 164 152 184 177 230 253
 CR 0.7 0.6 0.8 0.7 0.9 1.0
 ASR 0.6 0.5 0.6 0.6 0.7 0.8 6.5
a)Official registration employing ICD-O-3 began in 2003 at KCCR, 
b)The annual percent change is statistically significantly different from zero 
(P＜0.05).
Abbreviations: CR, crude incidence rate; ASR, age-standardized incidence rate; APC, annual percentage change; MPD, myeloproliferative 
disorders; MDS, myelodysplastic syndromes.
incidence rate of MDS was reported to have increased during 
those times, but the active engagement of registration during 
those times could have played a role behind the increase 
[13]. The APC for domestic MDS, MPD were also high be-
tween 2003 and 2008, but longer observation of changes 
in incidence should be implemented.
Multiple factors were thought to have played role in the 
increase of hematologic malignancies in Korea. Age, in-
fection, genetics, and other environmental factors were sug-
gested as causes of hematologic malignancies, but the exact 
cause would be difficult to explain [14-17]. According to 
Europe’s HAEMACARE project, the incidence of hemato-
logic malignancies in Europe also increased as age increased 
[3]. The aging of Korean population structure could be one 
factor for the increase of hematologic malignancies; however, 
our study showed significant increase of age-adjusted APC 
in most of the hematologic malignancies, and it cannot be 
explained solely by aging. Incidences of all hematologic dis-
eases were lower in women than men, similar with results 
of Europe’s HAEMACARE project. For the explanation of 
this phenomenon, there had been many interpretation in-
cluding environmental and occupational risk factor, smoking, 
alcohol consumption, susceptibility to cancer, and hormonal 
and genetic differences between men and women [18-20].Korean J Hematol 2012;47:28-38.
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Fig. 3. Age-specific incidence rates of hematologic malignancies in Korea, 2008. (A) Men. (B) Women.
 
Fig. 4. Five-year survival rate of 
hematologic malignancies from 
1993 to 2008 in Korea. 
a)Official 
registration employing ICD-O-3 
began in 2003 at KCCR.Korean J Hematol 2012;47:28-38.
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Table 4. Five-year relative survival rates of hematologic malignancies by gender and age group in Korea.
Cancer
type
Gender
Age 
(yr)
Year
Change
a) 1993-1995 1996-2000 2001-2005 2004-2008
Cases
Relative 
survival
Cases
Relative 
survival
Cases
Relative 
survival
Cases
Relative 
survival
Hematologic Total 0-14 1,217 51.7  2,305 61.8  2,462 71.9  2,377 73.3  21.6
  malignancies 15-34 1,809 39.5  3,402 49.6  3,871 62.3  4,159 70.3  30.8
  (Total) 35-49 1,671 42.4  4,085 49.7  5,948 62.1  6,790 66.8  24.4
50-64 2,243 34.2  5,610 40.4  7,888 51.5  9,516 56.7  22.5
65-79 1,261 25.2  3,738 26.5  6,906 33.1  9,396 36.9  11.7
≥80 92 18.0  390 24.4  905 19.8  1,382 22.3  4.3
Men 0-14 755 50.4  1,369 60.9  1,518 71.4  1,416 73.9  23.5
15-34 1,042 38.5  1,968 45.7  2,228 59.3  2,388 68.5  30.0
35-49 1,015 43.2  2,450 48.4  3,481 60.4  3,924 64.9  21.7
50-64 1,327 33.1  3,253 38.6  4,547 48.5  5,508 53.6  20.5
65-79 711 21.9  1,990 26.1  3,726 33.1  5,022 35.5  13.6
≥80 42 24.5  176 19.5  456 17.9  681 20.7  -3.8
Women 0-14 462 53.8  936 63.0  944 72.7  961 72.5  18.7
15-34 767 40.9  1,434 55.0  1,643 66.3  1,771 72.7  31.8
35-49 656 41.1  1,635 51.6  2,467 64.4  2,866 69.5  28.4
50-64 916 35.8  2,357 42.8  3,341 55.5  4,008 60.8  25.0
65-79 550 29.2  1,748 27.0  3,180 33.0  4,374 38.4  9.2
≥80 50 13.2  214 28.0  449 21.4  701 23.9  10.7
Hodgkin Total 0-14 26 84.8 37 94.7 60 95.1 67 95.6 10.8
  lymphoma 15-34 102 79.9 186 88 288 88 318 91.1 11.2
35-49 57 75.4 131 73.1 161 83.8 178 89.1 13.7
50-64 51 50.4 129 56.7 161 63.6 182 75 24.6
65-79 29 39.5 75 43.6 99 40.6 134 49.3 9.8
≥80 4 0 5 0 14  22.3 20  21.8 21.8
Men 0-14 20 85.3 24 96 38 94.8 43 95.4 10.1
15-34 54 78.4 102 86.8 159 85.2 168 88.3 9.9
35-49 41 82.8 101 73.9 128 84.2 134 88.1 5.3
50-64 37 47.1 105 51 122 62.9 140 74.2 27.1
65-79 17 31.1 43 44.2 72 40.7 92 45.9 14.8
≥8 0 2  0 3  06  06  0 0
Women 0-14 6 83.5 13 92.4 22 95.5 24 95.9 12.4
15-34 48 81.5 84 89.5 129 91.5 150 94.5 13
35-49 16 56.7 30 70.5 33 82.3 44 92.9 36.2
50-64 14 59.1 24 81.3 39 65.7 42 77.9 18.8
65-79 12 51.1 32 42.8 27 40.3 42 55.2 4.1
≥80 2 0 2 0 8  37.6 14  33 33
Non-Hodgkin Total 0-14 226 61.7 452 69.6 525 80.8 534 78.6 16.9
  lymphoma 15-34 638 51.1 1,274 60.2 1,482 71 1,617 78.9 27.8
35-49 811 57 2,023 62.2 2,830 70.9 3,242 74.7 17.7
50-64 1,166 45.5 2,935 50.3 3,833 62.5 4,521 66.7 21.2
65-79 706 33.3 2,013 34.8 3,261 41.6 4,205 45.6 12.3
≥80 57 22.2 254 30 505 24.4 707 26.9 4.7
Men 0-14 161 60.4 298 67.3 365 80.9 364 80.6 20.2
15-34 383 48.7 775 55.6 847 66.6 918 75.6 26.9
35-49 540 56.4 1,284 60.3 1,669 67.7 1,877 70.6 14.2
50-64 715 42.8 1,722 48 2,245 58.4 2,634 63.3 20.5
65-79 402 29.5 1,125 33.6 1,766 41.9 2,253 44.8 15.3
≥80 23 35.4 108 22.3 259 19.8 336 23.9 -11.5
Women 0-14 65 64.7 154 74.2 160 80.6 170 73.9 9.2
15-34 255 54.7 499 67.3 635 76.8 699 83.2 28.5
35-49 271 58.1 739 65.5 1,161 75.5 1,365 80.3 22.2
50-64 451 49.7 1,213 53.6 1,588 68.2 1,887 71.5 21.8
65-79 304 38.1 888 36.3 1,495 41.2 1,952 46.5 8.4
≥80 34 14.5 146 35.2 246 28.8 371 30.3 15.8
Multiple Total 0-14 1 101.2 1 100.1 3  33.4 3  66.7 -34.5
  myeloma 15-34 25 60.4 30 53.6 32 72.2 38 73.1 12.7
35-49 99 32 281 30.8 390 44.7 419 49.5 17.5
50-64 334 22.5 856 21.3 1,146 33.8 1,353 41.4 18.9
65-79 199 14 695 13 1,254 19.3 1,660 22.9 8.9
≥80 10 0 43  18.3 131 9 202  12.6 12.6Korean J Hematol 2012;47:28-38.
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Table 4. Continued.
Cancer
type Gender Age 
(yr)
Year
Change
a) 1993-1995 1996-2000 2001-2005 2004-2008
Cases Relative 
survival Cases Relative 
survival Cases Relative 
survival Cases Relative 
survival
Men 0-14 - - - - - - - - -
15-34 15 60.6 19 42.4 22 68.5 26 69.4 8.8
35-49 54 32.5 172 25 249 45.3 255 51.1 18.6
50-64 193 22.8 479 19 641 30.7 737 38 15.2
65-79 105 11.1 349 12.1 628 20.7 799 24 12.9
≥80 9 0 27  22.5 63 5.9 99 6.2 6.2
Women 0-14 1 101.2 1 100.1 3  33.4 3  66.7 -34.5
15-34 10 60.2 11 73 10 80.2 12 81.2 21
35-49 45 31.4 109 39.8 141 43.6 164 46.3 14.9
50-64 141 22.1 377 24.1 505 37.7 616 45.5 23.4
65-79 94 17 346 13.8 626 18 861 21.9 4.9
≥80 1  0 16 11.8 68 11.6 103 16.6 16.6
≥80 3 0 11 0 13  12 18  24.1 24.1
Lymphoid Total 0-14 663 57.2 1,190 67.8 1,211 76.8 1,156 77.4 20.2
  leukemia 15-34 293 19.2 557 26.5 482 34.2 509 39.6 20.4
35-49 143 17.8 260 23.4 345 28.5 362 31.1 13.3
50-64 111 19.1 266 26.3 310 30.3 381 29.5 10.4
65-79 66 22.8 162 19.4 283 29.5 348 34.3 11.5
≥80 4 0 17 0 27  12.4 39  31.6 31.6
Men 0-14 396 55.7 684 66.9 725 75.5 649 76.8 21.1
15-34 174 20.8 326 24.7 295 31.2 312 40 19.2
35-49 82 12.5 138 22.2 196 27.8 206 28.7 16.2
50-64 55 15.8 150 26.7 157 28 222 24.5 8.7
65-79 37 14 86 21.7 161 27.4 187 27.7 13.7
≥80 1 0 6 0 14  13.3 21  39.1 39.1
Women 0-14 267 59.3 506 68.9 486 78.9 507 78.3 19
15-34 119 16.9 231 29.1 187 38.9 197 39.1 22.2
35-49 61 24.8 122 24.8 149 29.5 156 34.2 9.4
50-64 56 22.2 116 25.8 153 32.6 159 35.4 13.2
65-79 29 33.5 76 16.8 122 31.8 161 43.1 9.6
Myeloid Total 0-14 298 28.3 615 41.7 585 51.7 531 56 27.7
  leukemia 15-34 730 29.5 1,292 41.5 1,356 53.8 1,301 63.4 33.9
35-49 532 22 1,285 33.1 1,726 50.7 1,778 56.7 34.7
50-64 548 14.6 1,239 22.7 1,627 31.4 1,803 38.2 23.6
65-79 252 7.4 721 9.1 1,251  14.4 1,542  18.1 10.7
≥80 17  22.5 64 5.8 136 5.9 206  14 -8.5
Men 0-14 176 24.5 356 40.8 341 50.4 309 57.7 33.2
15-34 408 29.2 715 37.2 774 53.6 738 64.4 35.2
35-49 288 21.7 708 30.6 960 49.8 986 56.3 34.6
50-64 314 15.6 713 22.8 921 30 1,034 35.9 20.3
65-79 147 8.1 350 7 662  14.4 847  17.5 9.4
≥80 7 32.7 28  0 64 10.5 109 19.2 -13.5
Women 0-14 122 33.7 259 42.9 244 53.6 222 53.8 20.1
15-34 322 29.9 577 46.9 582 54 563 62.1 32.2
35-49 244 22.3 577 36.1 766 51.8 792 57.2 34.9
50-64 234 13.2 526 22.5 706 33.1 769 41.1 27.9
65-79 105  6.4 371 11 589 14.3 695 18.7 12.3
≥80 10  16.5 36 9 72 2.3 97 8.4 -8.1
MPD
b) Total 0-14 19 100.2
15-34 168 96.6
35-49 452 93.7
50-64 667 90.7
65-79 692 72.6
≥80 91 48.2
Men 0-14 12 100.2
15-34 97 97
35-49 266 92.7
50-64 375 90.9
65-79 359 68.1
≥80 44 68.1Korean J Hematol 2012;47:28-38.
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Table 4. Continued.
Cancer
type
Gender
Age 
(yr)
Year
Change
a) 1993-1995 1996-2000 2001-2005 2004-2008
Cases
Relative 
survival
Cases
Relative 
survival
Cases
Relative 
survival
Cases
Relative 
survival
Women 0-14 7 100.1
15-34 71 96
35-49 186 94.5
50-64 292 90.3
65-79 333 76.7
≥80 47 35.7
MDS
b) Total 0-14 67 69.7
15-34 208 69.1
35-49 359 59.1
50-64 609 43.6
65-79 815 25
≥80 117 9.8
Men 0-14 39 61.6
15-34 129 64.2
35-49 200 57.5
50-64 366 36
65-79 485 18.9
≥80 66 3.5
Women 0-14 28 84
15-34 79 77.5
35-49 159 61.7
50-64 243 56.6
65-79 330 33.7
≥80 51 24.4
a)Change in the 5-year relative survival between 1993-1995 and 2004-2008 as a percentage, 
b)Official registration employing ICD-O-3 began 
in 2003 at KCCR.
Abbreviations: MPD, myeloproliferative disorders; MDS, myelodysplastic syndromes.
Fig. 5. Number of prevalent cases 
of hematologic malignancies by 
time since diagnosis in January 1, 
2009 in Korea. 
a)Because official 
registration for MPD and MDS 
began in 2003, 5-10 year pre-
valence cases for these cancers are
underestimated.Korean J Hematol 2012;47:28-38.
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Table 5. International comparison of age-standardized incidence rates of hematologic malignancies.
Gender Cancer type ICD-10 code Korea Japan China France Germany UK Canada USA
Men Hodgkin lymphoma C81 0.5 0.5 0.5 2.3 1.8 2.8 2.7 2.6
Non-Hodgkin lymphoma C82-85, C96 6.7 6.3 2.5 11.6 9.3 12.4 15.2 16.3
Multiple myeloma
a) C88, C90 1.6 1.6 0.4 4.6 3.4 4.1 4.5 4.8
Leukemia C91-95 5.6 5.5 5.3 10.2 8.4 9.0 11.8 12.1
Women Hodgkin lymphoma C81 0.3 0.3 0.3 2.7 1.4 2.1 2.2 2.2
Non-Hodgkin lymphoma C82-85, C96 4.7 4.0 1.7 7.9 7.0 8.7 11.4 11.5
Multiple myeloma
a) C88, C90 1.1 1.1 0.3 2.9 2.3 2.6 3.1 3.0
Leukemia C91-95 4.1 3.1 4.7 6.5 5.4 5.7 6.8 7.9
Age-standardized incidence rates using the WHO world standard population, for Korea, data are from Korea National Cancer Incidence 
Database (KNCI DB), for all other countries, data are from GLOBOCAN 2008.
a)Multiple myeloma in Korea includes C90.
The survival rates have continuously improved in all hem-
atologic malignancies in Korea. According to recent 
NORDICAN database published by Nordic countries-Den-
mark, Finland, Norway, and Sweden, the 5-year survival 
rates of HL, NHL, multiple myeloma, and leukemia in those 
4 countries from 1999 to 2003 were similar to our survival 
rates, and also the 5-year survival rates of hematologic malig-
nancy patients in Hong Kong from 1996 to 2001 were com-
parable to our levels [1, 21].
However, our survival rates in most of the hematologic 
malignancies do not reach the levels that of the USA [22], 
and this difference in survival rates could be due to the 
different prevalent disease type as well as other complex 
factors. There were big differences in survival rates in domes-
tic hematologic malignancies before and after year 2000; 
however, in comparison of years between 2001-2005 and 
2004-2008, the increase of survival rates were less distinct 
with only 3% and 0.5% increase of survival rates in NHL, 
and lymphoid leukemia, respectively.
Just like other malignancies, there is an increase of long 
term survivors in hematologic malignancies. As seen in this 
study, there were more than 30,000 patients with 10-year 
prevalence treated for hematologic malignancies, and this 
is comparable to long term survivors of cervical cancer, liver 
cancer, and lung cancer [23]. Due to the improvements in 
treatment, more long term survivors of hematologic malig-
nancies will be observed. The increase of long term survivors 
after treatment for cancers including hematologic malig-
nancies may lead to various physical, psychological, and so-
cial problems after the cure of malignancies [24]. While 
we should try on improving the survival rate of the patients, 
further study involving the overall quality of life of long 
term survivors of hematologic malignancies would be 
needed.
Statistics for hematologic malignancies increases the un-
derstanding of overall hematologic malignancies, and it could 
be used as the basic information to help investigate epidemio-
logic characteristics, evaluate progress during the past years, 
and establish future strategies for hematologic malignancies. 
For more detailed analysis and international comparison, 
the hematologic malignancies registration program in Korea 
should be set up, and continuous effort and feedback between 
the Korean Society of Hematology and Korea Central Cancer 
Registry would be needed.
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